Save the date: BONESUPPORT Capital Markets Days to be held in Stockholm and London
Lund, Sweden, 11:00 CET, 24 August 2018 - BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, invites analysts and investors to its Capital Markets Days to take place in Stockholm and London.
Capital Markets Days:
- 19 September 2018 at 9:00am – 12.00 pm (Stockholm)
- 20 September 2018 at 9:30am – 12.30 pm (London)
Speakers at the events from BONESUPPORT’s Executive Management Team will be CEO Emil Billbäck, CFO Björn Westberg, Dr Michael Diefenbeck, Head of R&D, Medical and Clinical Affairs and Patrick O’ Donnell, Executive Vice President Commercial Operations North America.
A formal invitation with a complete agenda will be sent out around two weeks before the meetings. The Capital Markets Day will be held in English. Further information will be available on the Company’s website www.bonesupport.com prior to the event.
For more information contact:
BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Björn Westberg, CFO
+46 (0) 46 286 53 60
Citigate Dewe Rogerson
Pip Batty, David Dible, Shabnam Bashir
+44 (0)20 7282 1022
bonesupport@citigatedewerogerson.com
About BONESUPPORT™
BONESUPPORT is an innovative commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.
BONESUPPORT’s bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary technology platform.
The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis), ortho-oncology, foot and ankle, and infected diabetic foot.
BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.
The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.
In addition, BONESUPPORT is looking to expand its product offering in the US and has entered into a strategic agreement with MTF Biologics and Collagen Matrix Inc. to market and distribute products that are complementary to CERAMENT BVF.
BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com
*CERAMENT G: Not available in the United States, for investigational use only.
CERAMENT V: Not available in the United States.
BONESUPPORT™ and CERAMENT® are registered trademarks.
The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CET on 24 August 2018.